Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference
- New data from multi-dose GLP toxicology study of SNS-101 in cynomolgus monkeys further support exceptional PK and safety profile -
- Mechanistic mouse data show SNS-101 drives tumor macrophages to adopt an immunostimulatory, anti-tumor phenotype -
BOSTON, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today will present new preclinical data from SNS-101, a clinical-stage conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), at the Seventh Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, held on September 20 – 23, 2023 in Milan, Italy.
“We believe these data further support the potential best-in-class PK and safety profile of SNS-101 and its ability to effectively target VISTA, a promising, but difficult-to-drug immune checkpoint,” said Edward van der Horst, Ph.D., Chief Scientific Officer of Sensei Biotherapeutics. “Restricting drug activity to low pH conditions, such as those found in the acidic tumor microenvironment, allowed us to safely dose SNS-101 in our multi-dose NHP study at increasing levels while maintaining linear elimination kinetics and displaying no target-mediated drug disposition or adverse effects. Paired with new mechanistic data showing SNS-101 can shift immunosuppressive macrophages towards an anti-tumor phenotype, we believe SNS-101 could provide a transformative treatment option for patients. We look forward to sharing data from our ongoing clinical trial later this year.”
Sensei is evaluating SNS-101 in a Phase 1/2 clinical trial in patients with advanced solid tumors, and expects to report initial monotherapy pharmacokinetic and safety data by year-end 2023. Topline monotherapy and initial combination data are anticipated in 2024.
The full poster is available for viewing on Sensei’s website and will be on display at the conference during Poster Session A, being held today, September 21, 2023, from 12:30 pm to 2:00 pm CET.
About Sensei Biotherapeutics:
Cautionary Note Regarding Forward-Looking Statements
Keynote Panel: The Continued Rise of AI: Embracing the Known and Unknown to Drive Business Results
Building Brands in the Metaverse
The Basics: Architecture & Platform Integration